- Policy
- Pirespa·Kanarb are the targets of drug price negotiations
- by Lee, Hye-Kyung Oct 17, 2020 06:37am
- Ildong's 'Pirespa 200mg (Pirfenidone)' and Boryung's 'Kanarb 30, 60, 120mg (Fimasartan potassium)' and other drugs with increased usage were targeted for the price-volume agreement negotiation system monitoring. Roche Korea's 'Zelboraf 240mg (Vemurafenib)', Pfizer Korea's 'Inlyta1·5mg (Axitinib)', and Ipsen's 'Dysport (Clostridium botul
- Policy
- Atozet latecomer CKD Atoezy wins approval without PMS
- by Lee, Tak-Sun Oct 17, 2020 06:36am
- Chong Kun Dang has reportedly received the South Korean health authority’s approval on a follow-on drug of MSD’s dyslipidemia treatment Atozet. The approval preceded Atozet’s post-marketing surveillance (PMS) end date on Jan. 22 next year by three months, putting the latecomer on an advantageous position. However, the estimated l
- Opinion
- [Reporter's View] Vaccine's Cold Chain& Distribution System
- by Oct 17, 2020 06:36am
- Shinsung Pharm in charge of distribution of the flu vaccine at room temperature is being criticized. Shinsung Pharm itself has acknowledged the fault in the distribution process and is waiting for the disposal of the health authorities. The pharmaceutical distribution industry, which has been mainly dealing with synthetic drugs and OTC dru
- Policy
- 13,000 Allergan breast implant recipient data missing
- by Lee, Hye-Kyung Oct 17, 2020 06:36am
- Apparently, the information on 13,000 patients who received Allergan’s textured breast implant has not been fully surveyed, yet. In August last year, South Korea’s Ministry of Food and Drug Safety (MFDS) has ordered healthcare providers to halt using the implant and recalled the products as a patient, who received the implant, has been dia
- Company
- Different use different price for same substance drugs?
- by Eo, Yun-Ho Oct 15, 2020 06:06am
- One says “Why should drugs cost the same when their effects, target patient sizes and values are different?” Another argues, “Why should I pay more for a drug that shares a common substance with other drugs?” In some way, both of those arguments make sense. And it is considered a conventional conflict of interest between a seller and
- Company
- The patent dispute over Otezla is expected to be fierce
- by Kim, Jin-Gu Oct 15, 2020 06:06am
- The patent dispute over the psoriasis treatment 'Otezla (Apremilast)' is expected to be fierce. In 15 days, eight companies had a patent challenge. Considering the fact that this treatment has not yet been officially released in Korea, it is evaluated that it is receiving great attention from domestic companies. According to the pharmac
- Company
- SK Biopharm, to export technology for XCOPRI to Japan
- by An, Kyung-Jin Oct 15, 2020 06:05am
- SK Biopharm announced on the 13th that it has signed a technology export contract for the development and commercialization of XCOPRI (Cenobamate), a new epilepsy drug, in Japan with Ono Pharma. With this contract, SK Biopharm secured ¥5 billion (approximately &8361;54.5 billion) in a down payment without obligation to return it. It
- Policy
- Insurance benefits for Vizimpro·Ferinject were passed
- by Lee, Hye-Kyung Oct 15, 2020 06:05am
- Pfizer Pharmaceutical Korea's non-small cell lung cancer treatment 'Vizimpro (Dacomitinib)' was recognized as reimbursement drug. Eisai Korea's Equfina 50mg (Safinamide mesylate), an adjuvant therapy for Parkinson's disease patients, and JW Pharmaceutical's iron formulation,'Ferinject inj (Ferric hydroxide carboxymaltose complex)', also pass
- Policy
- The number of generics in Korea is more than 10 times higher
- by Lee, Jeong-Hwan Oct 14, 2020 06:24am
- It is pointed out that the number of generic drugs with the same active ingredient licensed in Korea is “more than 10 times higher” in foreign countries such as the United States and France. This is the result of comparing the top five items with the largest number of domestic marketing generics with overseas cases. In particular, it was
- Policy
- “Riavax problem even noticeable for incompetent officer"
- by Lee, Jeong-Hwan Oct 14, 2020 06:24am
- Witnesses at National Assembly annual audit reproached Riavax, the immunotherapeutic peptide for pancreatic cancer treatment revoked from marketing approval, has apparently submitted review materials that every researcher at Ministry of Food and Drug Safety (MFDS) would notice how they were poorly prepared. Regardless of the failure in g
